In this study, grade III and grade IV gliomas clearly have a poor functional prognosis, 1 year after surgery, and grade II gliomas with IDH mutation have better functional prognosis similar to grade I, 1 year after surgery. The gene discussed is IDH1; the disease is central nervous system cancer.